NEW HORIZON HEALTH LIMITED Financials New Horizon Health Limited OTC Markets
Equities
NHZHF
KYG6485S1021
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | -.--% |
| Apr. 08 | New Horizon Health Limited Announces Board Appointments | CI |
| Mar. 28 | New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 7,738 | 6,684 | 5,861 | 5,861 | - |
| Enterprise Value (EV) 1 | 6,119 | 5,797 | 5,166 | 5,587 | 5,384 |
| P/E ratio | -2.21 x | -81.8 x | 228 x | 19 x | 8.66 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 36.4 x | 8.74 x | 3.2 x | 2.06 x | 1.55 x |
| EV / Revenue | 28.8 x | 7.58 x | 2.82 x | 1.96 x | 1.43 x |
| EV / EBITDA | -24.4 x | -50.8 x | 144 x | 11.2 x | 4.42 x |
| EV / FCF | - | -12.3 x | -22 x | -14.6 x | -89.9 x |
| FCF Yield | - | -8.11% | -4.55% | -6.86% | -1.11% |
| Price to Book | 3.64 x | 3.1 x | 2.18 x | 1.93 x | 1.57 x |
| Nbr of stocks (in thousands) | 429,740 | 429,992 | 448,718 | 448,718 | - |
| Reference price 2 | 18.01 | 15.54 | 13.06 | 13.06 | 13.06 |
| Announcement Date | 3/18/22 | 3/13/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 70.57 | 212.8 | 765 | 1,830 | 2,848 | 3,777 |
| EBITDA 1 | - | -250.3 | -114.1 | 36 | 501 | 1,219 |
| EBIT 1 | - | -284.9 | -163.1 | -82.03 | - | - |
| Operating Margin | - | -133.93% | -21.32% | -4.48% | - | - |
| Earnings before Tax (EBT) 1 | - | -3,085 | -79.66 | 6.794 | 361.5 | 783.2 |
| Net income 1 | - | -3,085 | -79.24 | 13.04 | 315.1 | 663.8 |
| Net margin | - | -1,450.14% | -10.36% | 0.71% | 11.06% | 17.58% |
| EPS 2 | -6.640 | -8.150 | -0.1900 | 0.0573 | 0.6869 | 1.509 |
| Free Cash Flow 1 | - | - | -470.4 | -235.3 | -383 | -59.9 |
| FCF margin | - | - | -61.5% | -12.86% | -13.45% | -1.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 3/15/21 | 3/18/22 | 3/13/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|
| Net sales 1 | 43.93 | 168.8 | 225.7 | 539.3 | 822.7 | 702.9 |
| EBITDA | - | - | - | - | - | - |
| EBIT | -115.1 | -169.9 | -112 | -51.14 | -32.06 | - |
| Operating Margin | -261.92% | -100.62% | -49.62% | -9.48% | -3.9% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS | - | 0.4300 | -0.1500 | -0.0400 | 0.2600 | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/20/21 | 3/18/22 | 8/19/22 | 3/13/23 | 8/21/23 | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,619 | 886 | 695 | 274 | 477 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -470 | -235 | -383 | -59.9 |
| ROE (net income / shareholders' equity) | - | -145% | -3.73% | -2.44% | 10.7% | 19.7% |
| ROA (Net income/ Total Assets) | - | - | - | 0.8% | 6.88% | 16.6% |
| Assets 1 | - | - | - | 1,631 | 4,578 | 3,991 |
| Book Value Per Share 2 | - | 4.950 | 5.020 | 6.000 | 6.750 | 8.340 |
| Cash Flow per Share 2 | - | - | - | -0.4600 | 0.2800 | 1.290 |
| Capex 1 | - | 37.1 | 57.9 | 67 | 102 | 128 |
| Capex / Sales | - | 17.44% | 7.57% | 3.66% | 3.57% | 3.4% |
| Announcement Date | 3/15/21 | 3/18/22 | 3/13/23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.06
CNY
Average target price
29.42
CNY
Spread / Average Target
+125.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.55% | 11.67B | |
| -5.68% | 8B | |
| +6.78% | 5.72B | |
| +27.87% | 5.5B | |
| -15.84% | 3.84B | |
| +10.70% | 2.66B | |
| -60.36% | 2.66B | |
| -9.66% | 2.3B | |
| +15.94% | 2.01B |
- Stock Market
- Equities
- 6606 Stock
- NHZHF Stock
- Financials New Horizon Health Limited
